Avalo Therapeutics (AVTX) Receivables - Other (2016 - 2024)
Avalo Therapeutics (AVTX) reported Receivables - Other of -$600000.0 for Q4 2024, down 20.0% on a YoY basis from -$750000.0 in Q1 2024, and up 33.33% quarter-over-quarter from -$900000.0 in Q3 2024.
Avalo Therapeutics (AVTX) Receivables - Other (2016 - 2024) Analysis & Trends
Avalo Therapeutics has reported Receivables - Other for 9 years, with the latest figure at -$600000.0 in Q4 2024.
- For the quarter ending Q4 2024, Receivables - Other fell 20.0% year-over-year to -$600000.0; the trailing twelve-month figure through Dec 2024 stood at -$600000.0 (down 20.0% YoY), and the FY2024 full-year result was $611000.0, up 222.2% from the prior year.
- Receivables - Other for Q4 2024 stood at -$600000.0, up from -$900000.0 in the prior quarter.
- The five-year high for Receivables - Other was $4.3 million in Q3 2020, with the low at -$900000.0 in Q3 2024.
- Historically, Receivables - Other has averaged $1.3 million across 5 years, with a median of $1.3 million in 2022.
- Annual changes were most pronounced in 2020 — Receivables - Other soared 1958.27% — and 2024, when it slumped 158.52%.
- Avalo Therapeutics' Receivables - Other stood at $2.2 million in 2020, then soared by 69.34% to $3.7 million in 2021, then sank by 48.68% to $1.9 million in 2022, then slumped by 126.06% to -$500000.0 in 2023, then slipped by 20.0% to -$600000.0 in 2024.
- The last three Receivables - Other figures came in at -$600000.0 (Q4 2024), -$900000.0 (Q3 2024), and $33000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -600,000.00 |
| Dec 31, 2024 | -600,000.00 |
| Sep 30, 2024 | -900,000.00 |
| Sep 30, 2024 | -900,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Dec 31, 2023 | -500,000.00 |
| Dec 31, 2023 | -500,000.00 |
| Sep 30, 2023 | 1.54 Mn |
| Sep 30, 2023 | 1.54 Mn |
| Jun 30, 2023 | 6,000.00 |
| Jun 30, 2023 | 6,000.00 |
| Mar 31, 2023 | 857,000.00 |
| Mar 31, 2023 | 857,000.00 |
| Dec 31, 2022 | 1.92 Mn |
| Dec 31, 2022 | 1.92 Mn |
| Sep 30, 2022 | 1.31 Mn |
| Sep 30, 2022 | 1.31 Mn |